Embla Medical hf.
OSSFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.77 | 0.73 | -1.07 | 0.05 |
| FCF Yield | 4.45% | 3.06% | 2.30% | 2.70% |
| EV / EBITDA | 12.75 | 14.64 | 16.26 | 20.58 |
| Quality | ||||
| ROIC | 6.16% | 5.45% | 5.55% | 6.41% |
| Gross Margin | 58.52% | 57.83% | 56.77% | 58.59% |
| Cash Conversion Ratio | 1.03 | 1.62 | 1.43 | 1.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.96% | 3.02% | 4.51% | 1.55% |
| Free Cash Flow Growth | 47.64% | 49.43% | -52.83% | 8.24% |
| Safety | ||||
| Net Debt / EBITDA | 2.46 | 2.76 | 3.42 | 2.41 |
| Interest Coverage | 4.56 | 4.22 | 6.58 | 7.49 |
| Efficiency | ||||
| Inventory Turnover | 2.48 | 2.43 | 2.35 | 2.86 |
| Cash Conversion Cycle | 175.03 | 178.17 | 180.84 | 148.93 |